A research programme by the Access to Medicine Foundation
The foundation

Access to Medicine Foundation

The Foundation stimulates and guides pharmaceutical companies to do more to improve access to medicine. It is an independent non-profit organisation.
Our programmes

Access to Medicine Index

Ranks 20 of the world’s largest pharmaceutical companies based on their efforts to address access to medicine, including in strategy, governance, R&D and pricing. By publicly recognising the best performers, the Index spurs companies to compete to be the best.

Antimicrobial Resistance Benchmark

Tracks what the 30 most active companies in antimicrobial R&D and manufacturing are doing to bring antimicrobial resistance under control. By assessing the level of action, it provides a reality check on progress against AMR.

Access to Vaccines Index

Reports what vaccine companies are doing to ensure all children can be immunised wherever they live. By uncovering what is working and where, this Index helps ensure vaccine markets also reach the poorest and most remote communities.
Type search term(s) and press enter
Often searched for
Index Ranking Vacancies 10-year analysis R&D pipelines AMR antibiotics Investors
  • In the media
  • Research burden carried by a handful of drug...
Media - published on 20 Nov 2018

Research burden carried by a handful of drug companies, says report

Jyothi Datta of the Hindu Business Line reports on the results of the 2018 Access to Medicine Index. The article focuses on the handful companies carrying out the majority of urgently needed R&D. 

The piece features a quote from Jayasree K. Iyer, Executive Director of the Access to Medicine Foundation, on how the current situation looks: "The key message from the report is that if just a handful of companies are carrying the bulk of the priority and R&D load, it shows how fragile the situation is."

Learn more

View our detailed overview of each company’s performance in the Index, including breakdowns of their product portfolios and R&D pipelines.

Back to top |